IRIS
DE LUCA, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.497
AS - Asia 3.650
NA - Nord America 3.546
SA - Sud America 852
AF - Africa 84
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 13.638
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.413
RU - Federazione Russa 2.775
SG - Singapore 1.270
CN - Cina 1.195
BR - Brasile 707
RO - Romania 700
IT - Italia 544
SE - Svezia 474
HK - Hong Kong 452
VN - Vietnam 345
DE - Germania 268
FR - Francia 199
GB - Regno Unito 130
FI - Finlandia 108
IN - India 80
CA - Canada 72
NL - Olanda 70
AR - Argentina 64
AT - Austria 58
JP - Giappone 50
MX - Messico 43
PL - Polonia 42
ZA - Sudafrica 35
BD - Bangladesh 33
TR - Turchia 33
ES - Italia 30
ID - Indonesia 27
PH - Filippine 25
IQ - Iraq 23
EC - Ecuador 21
VE - Venezuela 18
PK - Pakistan 17
UA - Ucraina 17
LT - Lituania 16
CO - Colombia 15
UZ - Uzbekistan 14
AE - Emirati Arabi Uniti 13
IE - Irlanda 13
EG - Egitto 12
PY - Paraguay 12
KR - Corea 10
MA - Marocco 10
BE - Belgio 9
TN - Tunisia 9
CL - Cile 7
IR - Iran 7
PE - Perù 7
BH - Bahrain 6
NO - Norvegia 6
SA - Arabia Saudita 6
AZ - Azerbaigian 5
LU - Lussemburgo 5
MK - Macedonia 5
MY - Malesia 5
NP - Nepal 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
GR - Grecia 4
IL - Israele 4
KE - Kenya 4
KZ - Kazakistan 4
LB - Libano 4
XK - ???statistics.table.value.countryCode.XK??? 4
AU - Australia 3
CH - Svizzera 3
DZ - Algeria 3
HN - Honduras 3
JO - Giordania 3
LV - Lettonia 3
PT - Portogallo 3
AO - Angola 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
EU - Europa 2
HR - Croazia 2
HU - Ungheria 2
JM - Giamaica 2
MN - Mongolia 2
NI - Nicaragua 2
OM - Oman 2
PS - Palestinian Territory 2
SN - Senegal 2
TH - Thailandia 2
TW - Taiwan 2
AL - Albania 1
BB - Barbados 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
CU - Cuba 1
CY - Cipro 1
GA - Gabon 1
GT - Guatemala 1
KH - Cambogia 1
LC - Santa Lucia 1
LY - Libia 1
MD - Moldavia 1
PA - Panama 1
SI - Slovenia 1
Totale 13.634
Salva come PNG Salva come JPEG
Città #
Dallas 1.101
Singapore 663
Moscow 550
Ashburn 443
Hong Kong 443
San Jose 280
Shanghai 254
Beijing 190
Hefei 156
New York 151
Milan 135
Lauterbourg 133
Ho Chi Minh City 127
Los Angeles 107
Lawrence 99
Princeton 99
Munich 96
São Paulo 77
Boardman 63
Nuremberg 62
Helsinki 60
Hanoi 59
Rome 47
Orem 42
Tokyo 40
Santa Clara 38
Warsaw 35
Denver 33
Atlanta 32
Johannesburg 29
Rio de Janeiro 29
Chicago 28
Frankfurt am Main 28
Montreal 28
Chennai 27
Turku 27
Guangzhou 26
Council Bluffs 25
Cesano Boscone 23
Poplar 23
Stockholm 23
Da Nang 21
Lappeenranta 20
London 20
Falkenstein 19
Haiphong 18
Mexico City 18
Amsterdam 17
Ankara 17
Houston 17
Manchester 17
Vienna 17
Brooklyn 16
Seattle 15
Mumbai 14
Naples 13
Shenzhen 13
The Dalles 13
Tianjin 13
Buffalo 12
City of London 12
Tashkent 12
Belo Horizonte 11
Boston 11
Campinas 11
Dublin 11
New Delhi 11
Secaucus 11
Toronto 11
Istanbul 10
Padua 10
Phoenix 10
Porto Alegre 10
Xi'an 10
Can Tho 9
Makati City 9
Brasília 8
Brussels 8
Guayaquil 8
Hangzhou 8
Pune 8
Roubaix 8
Seongnam-si 8
Verona 8
Barnet 7
Biên Hòa 7
Columbus 7
Curitiba 7
Manaus 7
Marília 7
Paris 7
Phủ Lý 7
San Francisco 7
Turin 7
Zhengzhou 7
Ancona 6
Asunción 6
Baghdad 6
Bexley 6
Brescia 6
Totale 6.581
Salva come PNG Salva come JPEG
Nome #
Digital Ulcers and Ventricular Arrhythmias as Red Flags to Predict Replacement Myocardial Fibrosis in Systemic Sclerosis 453
Intercalated Disc Abnormalities Are Linked to Arrhythmias in Inflammatory Cardiomyopathy 423
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 373
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 344
Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: Frequency, clinical and prognostic correlates 229
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 222
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 180
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 166
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 151
Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities 141
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 141
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 138
B cells in systemic sclerosis: A possible target for therapy 132
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature 128
Does the impact of COVID-19 on patients with systemic sclerosis change over time? 125
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 125
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 124
Arrhythmias in Myocarditis: State of the Art 119
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 116
Clinical profiling and outcomes of viral myocarditis manifesting with ventricular arrhythmias 115
Pruritus characteristics in a large Italian cohort of psoriatic patients 115
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation 115
Distinctive clinical traits of lupus-related myocarditis: a multicentre retrospective study 115
A Novel Histiocytosis With Synovial and Skin Involvement 114
ASSOCIAZIONE TRA MALATTIA IGG4-CORRELATA E IMMUNOTERAPIA ALLERGENE-SPECIFICA. STUDIO EPIDEMIOLOGICO DI UN CENTRO DI RIFERIMENTO ITALIANO. 114
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 112
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 112
Exercise Stress Test Late after Arrhythmic versus Nonarrhythmic Presentation of Myocarditis 111
Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy 110
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 109
C3-glomerulopathy and MGUS: The skin beyond the kidney 108
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 105
Therapeutic strategies for primary heart involvement in systemic sclerosis 104
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 103
Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis 103
Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis 102
Calcinosis in systemic sclerosis: An update on pathogenesis, related complications, and management: A heavy burden still waiting to be lifted off patients’ hands 101
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 101
Drug retention rates of biological agents in adult onset Still's disease 101
Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases 101
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 99
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 99
Cardiovascular magnetic resonance parametric mapping in the risk stratification of patients affected by chronic myocarditis 99
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 98
Inflammation as a Predictor of Recurrent Ventricular Tachycardia After Ablation in Patients With Myocarditis 98
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 98
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 98
Advances in potential targeted therapies for Erdheim-Chester disease 97
The spectrum of covid-19-associated myocarditis: A patient-tailored multidisciplinary approach 97
Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis 94
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 94
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study 93
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 93
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 93
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 92
Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers 91
Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum 91
Multimodal Detection and Targeting of Biopsy-Proven Myocardial Inflammation in Genetic Cardiomyopathies: A Pilot Report 90
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 90
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 90
Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases 90
Cardiac involvement, a threatening very early manifestation of systemic sclerosis: evidence from VEDOSS patients 89
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 89
Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias 89
Anti-Ku syndrome with elevated CK: Association with myocardial involvement in systemic sclerosis 87
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies 87
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 86
Cardiac Sarcoidosis: Clinical Insights, Diagnosis, and Management Strategies 85
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series 85
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study 84
Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis 84
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 84
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 83
Pain and Frailty in Hospitalized Older Adults 82
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients 82
Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study 82
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 80
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies 80
Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both 78
Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group 77
The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis 77
MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION 73
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis 72
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study 72
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 72
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition 72
Corrigendum to “Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience” [Autoimmunity Reviews, Volume 20, Issue 12, December 2021, 102981](S1568997221002615)(10.1016/j.autrev.2021.102981) 70
Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst 70
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 69
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 69
Data standards for transcatheter aortic valve implantation: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) (October, qcac063, 2022) 68
Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation 68
Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it? 68
Telemedicine in myocarditis: Evolution of a mutidisciplinary “disease unit” at the time of COVID-19 pandemic 68
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 66
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 66
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis 65
Hybrid FDG-PET/MR or FDG-PET/CT to Detect Disease Activity in Patients With Persisting Arrhythmias After Myocarditis 64
QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk 63
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition 62
Totale 11.052
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.855
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.855
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 0 4 2
2021/2022249 1 0 102 46 9 16 4 7 11 31 5 17
2022/2023784 250 176 55 4 16 97 40 72 35 11 15 13
2023/2024744 25 56 75 67 65 111 42 82 5 33 36 147
2024/20253.364 224 41 102 104 130 218 1.093 331 388 233 200 300
2025/20268.810 612 868 944 1.147 707 286 724 665 2.473 384 0 0
Totale 14.038